Clinical Research Directory

Inclusion Criteria: Patients who meet all the following criteria will be included in this study: 1. Patients 18 years of age or older; 2. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening; 3. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time; 4. Patients who are willing to sign the informed consent form. Exclusion Criteria: Patients who meet any of the following exclusion criteria will be excluded from this study: 1. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium); 2. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution; 3. Patients with other contraindications specified in the prescribing information; 4. Patients concurrently participating in other clinical studies; 5. Patients under other conditions or circumstances that investigators do not consider appropriate to include.